SCHEMBL992647

SCHEMBL992647

C[Si](C)(C)c1cc(Cl)nnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 2/20 0.32
PKM P14618 1/20 0.32
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31226080 1.00 TDP1 (0.46) TDP1ALDH1A1PKMKDM4E
SCHEMBL10371039 0.78 TDP1 (0.40) TDP1
SCHEMBL611871 0.73 ALDH1A1 (0.35) TDP1ALDH1A1
SCHEMBL10370230 0.72 TDP1 (0.35) TDP1
SCHEMBL31226082 0.72 GAA (0.41) TDP1ALDH1A1KDM4E
SCHEMBL992666 0.72 GAA (0.41) TDP1ALDH1A1KDM4E
SCHEMBL29412411 0.69
SCHEMBL194096 0.67
SCHEMBL29549708 0.67
SCHEMBL21749477 0.65 TDP1 (0.41) TDP1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024245156-A1 HETEROCYCLIC COMPOUND ACTING AS α5-GABAA RECEPTOR REGULATOR 武汉人福创新药物研发中心有限公司 2024-12-05 WO disclosed
US-8993570-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-8993570-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-8993570-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20130317033-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2013-11-28 US disclosed
US-8501738-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-8501738-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-8501738-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
EP-2454259-A1 DEUTERIUM-MODIFIED TRIAZOLO-PYRIDAZINE DERIVATIVES AS GABA-A RECEPTOR MODULATORS Concert Pharmaceuticals Inc. (US) 2012-05-23 EP disclosed
US-20110065711-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2011-03-17 US disclosed
US-20110065711-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2011-03-17 US disclosed
WO-2011005520-A1 DEUTERIUM-MODIFIED TRIAZOLO-PYRIDAZINE DERIVATIVES AS GABA-A RECEPTOR MODULATORS CONCERT PHARMACEUTICALS, INC. (US) 2011-01-13 WO disclosed
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 US disclosed
CN-1110498-C Triazolo-pyridazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME (GB) 2003-06-04 CN disclosed
EP-1107967-B1 TRIAZOLOPYRIDAZINE DERIVATIVES FOR ENHANCING COGNITION MERCK SHARP & DOHME (GB) 2003-05-14 EP disclosed
CN-1288465-A Triazolo-pyridazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME (GB) 2001-03-21 CN disclosed
EP-1049696-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-11-08 EP disclosed
WO-1999037644-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 TDP1 2305/4885ALDH1A1 1373/4885PKM 1355/4885
US-20130317033-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES GABRA5, GABRA2, GABRA3 TDP1 2359/4885ALDH1A1 1152/4885PKM 1079/4885
US-20110065711-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES GABRA5, GABRA2, GABRA3 TDP1 2359/4885ALDH1A1 1152/4885PKM 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.